Antiplatelet Therapy in Diabetes

descriptionPublicationkeyboard_double_arrow_right Article 01 Mar 2018 English Publisher:Elsevier BVJournal:Endocrinology and Metabolism Clinics of North America, volume 47, pages 223-235 (issn: 0889-8529,

Copyright policy )

Authors: Arjun, Majithia; Deepak L, Bhatt;

doi: 10.1016/j.ecl.2017.10.009

pmid: 29407053

Antiplatelet Therapy in Diabetes

- Summary
- Subjects
- Metrics

Abstract

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality among patients with diabetes mellitus (DM). Increased platelet reactivity among patients with DM contributes to disproportionately high levels of atherothrombotic CVD. Consequently, there has been tremendous interest in exploring the role of antiplatelet therapies in DM to reduce the development of and frequency of future cardiovascular events.

Related Organizations

Brigham and Women's Faulkner Hospital
United States
Lahey Medical Center
United States

Keywords

Diabetes Complications, Aspirin, Cardiovascular Diseases, Humans, Platelet Aggregation Inhibitors

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average